Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 2361963, 6 pages
https://doi.org/10.1155/2018/2361963
Review Article

The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection

1Department of Clinical Laboratory, Translational Medicine Center, Huaihe Hospital Affiliated to Henan University, Kaifeng, Henan 475000, China
2Department of Nephrology, First Affiliated Hospital of Henan University, Kaifeng, Henan 475000, China

Correspondence should be addressed to Xuhong Lin; nc.ude.ijgnot@hxl627008

Received 5 January 2018; Revised 15 May 2018; Accepted 29 May 2018; Published 25 July 2018

Academic Editor: Lucia Conti

Copyright © 2018 Ruilin Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Global Hepatitis Report 2017, WHO, 2017, http://www.who.int/hepatitis.
  2. S. Beckebaum, M. Malagó, O. Dirsch et al., “Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation,” Clinical Transplantation, vol. 17, no. 6, pp. 554–559, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Castelnau, F. le Gal, M. P. Ripault et al., “Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up,” Hepatology, vol. 44, no. 3, pp. 728–735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Hartmann, W. C. Chen, and B. Schnabl, “The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease,” Frontiers in Physiology, vol. 3, p. 402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Lin, L. Zhou, J. Zhang, and B. Wang, “Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 5, pp. 5153–5160, 2015. View at Google Scholar
  6. M. Bhat, B. M. Arendt, V. Bhat, E. L. Renner, A. Humar, and J. P. Allard, “Implication of the intestinal microbiome in complications of cirrhosis,” World Journal of Hepatology, vol. 8, no. 27, pp. 1128–1136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Grąt, K. M. Wronka, M. Krasnodębski et al., “Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis,” Transplantation Proceedings, vol. 48, no. 5, pp. 1687–1691, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. D. E. Fouts, M. Torralba, K. E. Nelson, D. A. Brenner, and B. Schnabl, “Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease,” Journal of Hepatology, vol. 56, no. 6, pp. 1283–1292, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. H. Chou, W. H. Chien, L. L. Wu et al., “Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota,” Proceedings of the National Academy of Sciences, vol. 112, no. 7, pp. 2175–2180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Prendergast, P. Klenerman, and P. J. R. Goulder, “The impact of differential antiviral immunity in children and adults,” Nature Reviews Immunology, vol. 12, no. 9, pp. 636–648, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. K. N. Tsai, C. F. Kuo, and J. H. J. Ou, “Mechanisms of hepatitis B virus persistence,” Trends in Microbiology, vol. 26, no. 1, pp. 33–42, 2018. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Xu, Y. Huang, and J. Wang, “Gut microbiota modulate the immune effect against hepatitis B virus infection,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 34, no. 11, pp. 2139–2147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Busca and A. Kumar, “Innate immune responses in hepatitis B virus (HBV) infection,” Virology Journal, vol. 11, no. 1, p. 22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Zhang and M. Lu, “Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection,” Medical Microbiology and Immunology, vol. 204, no. 1, pp. 11–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Ma, E. Zhang, D. Yang, and M. Lu, “Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses,” Cellular & Molecular Immunology, vol. 12, no. 3, pp. 273–282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Visvanathan, N. A. Skinner, A. J. V. Thompson et al., “Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein,” Hepatology, vol. 45, no. 1, pp. 102–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Das, I. Sengupta, N. Sarkar et al., “Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line,” BMC Infectious Diseases, vol. 17, no. 1, p. 76, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Sekirov, S. L. Russell, L. C. M. Antunes, and B. B. Finlay, “Gut microbiota in health and disease,” Physiological Reviews, vol. 90, no. 3, pp. 859–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Fukui, “Gut microbiota and host reaction in liver diseases,” Microorganisms, vol. 3, no. 4, pp. 759–791, 2015. View at Publisher · View at Google Scholar
  20. K. Korpela, A. Salonen, L. J. Virta et al., “Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children,” Nature Communications, vol. 7, article 10410, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Sender, S. Fuchs, and R. Milo, “Revised estimates for the number of human and bacteria cells in the body,” PLoS Biology, vol. 14, no. 8, article e1002533, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Atarashi and K. Honda, “Microbiota in autoimmunity and tolerance,” Current Opinion in Immunology, vol. 23, no. 6, pp. 761–768, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Rajilić-Stojanović, D. M. Jonkers, A. Salonen et al., “Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?” The American Journal of Gastroenterology, vol. 110, no. 2, pp. 278–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Michail, M. Durbin, D. Turner et al., “Alterations in the gut microbiome of children with severe ulcerative colitis,” Inflammatory Bowel Diseases, vol. 18, no. 10, pp. 1799–1808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. L.-M. Haag and B. Siegmund, “Intestinal microbiota and the innate immune system – a crosstalk in Crohn’s disease pathogenesis,” Frontiers in Immunology, vol. 6, p. 489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. D. Forbes, G. van Domselaar, and C. N. Bernstein, “The gut microbiota in immune-mediated inflammatory diseases,” Frontiers in Microbiology, vol. 7, article 1081, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. F. R. Ponziani, S. Bhoori, C. Castelli et al., “Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease,” Hepatology, 2018. View at Publisher · View at Google Scholar
  28. H. C. Xing, L. J. Li, K. J. Xu et al., “Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia-reperfusion injury,” Journal of Gastroenterology and Hepatology, vol. 21, no. 4, pp. 647–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Lu, Z. Wu, W. Xu, J. Yang, Y. Chen, and L. Li, “Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients,” Microbial Ecology, vol. 61, no. 3, pp. 693–703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. D. W. Jun, K. T. Kim, O. Y. Lee et al., “Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients,” Digestive Diseases and Sciences, vol. 55, no. 5, pp. 1465–1471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wang, Y. Wang, X. Zhang et al., “Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients,” Frontiers in Microbiology, vol. 8, p. 2222, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Kang and Y. Cai, “Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy,” Journal of Hospital Infection, vol. 96, no. 4, pp. 342–348, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Brun, I. Castagliuolo, V. D. Leo et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 292, no. 2, pp. G518–G525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. H. Frazier, J. K. DiBaise, and C. J. McClain, “Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury,” Journal of Parenteral and Enteral Nutrition, vol. 35, 5_Supplement, pp. 14s–20s, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Seki and B. Schnabl, “Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut,” The Journal of Physiology, vol. 590, no. 3, pp. 447–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Bermudez-Brito, S. Muñoz-Quezada, C. Gomez-Llorente et al., “Cell-free culture supernatant of Bifidobacterium breve CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation,” PLoS One, vol. 8, no. 3, article e59370, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Borrelli, P. Bonelli, F. M. Tuccillo et al., “Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches,” Redox Biology, vol. 15, pp. 467–479, 2018. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. H. Paik, R. F. Schwabe, R. Bataller, M. P. Russo, C. Jobin, and D. A. Brenner, “Toll-like. Receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells,” Hepatology, vol. 37, no. 5, pp. 1043–1055, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Lin and J. Zhang, “Role of intestinal microbiota and metabolites on gut homeostasis and human diseases,” BMC Immunology, vol. 18, no. 1, p. 2, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Gao, L. Liu, and H. Wang, “Advances in immunomodulation of microbial unmethylated CpG DNA on animal intestinal tract--a review,” Acta Microbiologica Sinica, vol. 55, no. 5, pp. 543–550, 2015. View at Google Scholar
  41. N. Cools, A. Petrizzo, E. Smits et al., “Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?” Immunotherapy, vol. 3, no. 10, pp. 1203–1222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. U. Cinar, M. A. Islam, M. Pröll et al., “Evaluation of suitable reference genes for gene expression studies in porcine PBMCs in response to LPS and LTA,” BMC Research Notes, vol. 6, no. 1, p. 56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Lemaitre and S. E. Girardin, “Translation inhibition and metabolic stress pathways in the host response to bacterial pathogens,” Nature Reviews Microbiology, vol. 11, no. 6, pp. 365–369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Kawasaki, T. Kawai, and S. Akira, “Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity,” Immunological Reviews, vol. 243, no. 1, pp. 61–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Ignacio, C. I. Morales, N. O. S. Câmara, and R. R. Almeida, “Innate sensing of the gut microbiota: modulation of inflammatory and autoimmune diseases,” Frontiers in Immunology, vol. 7, p. 54, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Codella, L. Luzi, and I. Terruzzi, “Exercise has the guts: how physical activity may positively modulate gut microbiota in chronic and immune-based diseases,” Digestive and Liver Disease, vol. 50, no. 4, pp. 331–341, 2018. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Liang, S. Liang, Y. Zhang et al., “Oral administration of compound probiotics ameliorates HFD-Induced gut microbe dysbiosis and chronic metabolic inflammation via the G protein-coupled receptor 43 in non-alcoholic fatty liver disease rats,” Probiotics and Antimicrobial Proteins, pp. 1–11, 2018. View at Publisher · View at Google Scholar · View at Scopus
  48. D. S. Kwak, D. W. Jun, J. G. Seo et al., “Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease,” European Journal of Gastroenterology & Hepatology, vol. 26, no. 12, pp. 1353–1359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. R. D. Heath, C. Cockerell, R. Mankoo, J. A. Ibdah, and V. Tahan, “Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders,” Northern Clinics of Istanbul, vol. 5, no. 1, pp. 79–88, 2018. View at Publisher · View at Google Scholar
  50. T.-C. D. Shen, L. Albenberg, K. Bittinger et al., “Engineering the gut microbiota to treat hyperammonemia,” The Journal of Clinical Investigation, vol. 125, no. 7, pp. 2841–2850, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. D. Ren, Z. S. Ye, L. Z. Yang et al., “Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy,” Hepatology, vol. 65, no. 5, pp. 1765–1768, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Ma, H. Chen, C. Lan, and J. Ren, “Help, hope and hype: ethical considerations of human microbiome research and applications,” Protein & Cell, vol. 9, no. 5, pp. 404–415, 2018. View at Publisher · View at Google Scholar